Israeli Consortium Sets Shared Care Protocols for Female BRCA Carriers

The national consensus aims to reduce differences in surveillance and prevention across nine high-risk clinics as population screening identifies more women with BRCA mutations.

Israeli Consortium Sets Shared Care Protocols for Female BRCA Carriers Anna Shvets

A consortium representing Israel’s nine high-risk surveillance clinics has established shared clinical protocols for women who carry harmful BRCA1 or BRCA2 variants but have not had cancer. The recommendations cover surveillance, risk assessment and preventive surgery, with the goal of reducing differences in care between clinics.

The effort follows Israel’s publicly funded screening program for women of Ashkenazi Jewish ancestry, introduced in 2020. About 165,000 women were tested between mid-2021 and 2024, identifying roughly 2,350 carriers. The clinics collectively oversee about 4,500 carriers, many of whom would not previously have qualified for genetic testing because they had no personal cancer diagnosis or prominent family history.

What changes for breast screening

The new consensus recommends annual breast MRI and clinical examinations for younger carriers. For women in the next age group, it calls for annual MRI and annual mammography staggered six months apart. A single-view mammogram may be used for younger adults. The consortium also supports continuing surveillance for older people in good functional health with few other health problems.

Before the agreement, eight clinics used annual MRI, while one routinely used MRI twice a year for BRCA1 carriers. Clinics also differed on screening age limits, imaging during pregnancy and breastfeeding, and imaging after mastectomy. The consortium’s review weighed concerns including radiation exposure in younger women and the burden of false-positive results.

Where clinics differed

The review found existing agreement among clinics on several approaches, including risk-reducing removal of both breasts or ovaries and fallopian tubes, fertility preservation, oral contraception, hormone therapy after surgery and lifestyle counseling. Differences remained in ovarian screening before and after surgery and surveillance for cancers such as pancreatic and gastrointestinal cancers.

Multidisciplinary panels brought together specialists in genetics, oncology, radiology, reconstruction, gastroenterology and reproductive endocrinology. The consortium aligned its recommendations with guidance from the National Comprehensive Cancer Network and the European Society for Medical Oncology. The available account does not specify when each clinic will put the shared protocols into practice.

This report draws on information from BIOENGINEER.ORG.

Editorial checks passed Facts, figures and quotes checked against 1 source, 1 official or primary

Add Clinic Near Me as a preferred source on Google

Related stories